Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 Mg/mL) for Intravenous Infusion

Next Previous
Trial Profile

A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 Mg/mL) for Intravenous Infusion

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fenretinide (Primary)
  • Indications Anaplastic large cell lymphoma; Cutaneous T-cell lymphoma; Follicular lymphoma; Mycosis fungoides; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Sezary syndrome; Squamous cell cancer; T-cell lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors SciTech Development

Most Recent Events

  • 25 Mar 2026 According to a SciTech Development media release, Phase 1a trial is fully enrolled and nearing completion, and data support the advancement of ST-001 into the next phase of clinical development.
  • 25 Mar 2026 According to a SciTech Development media release, Phase 1a trial will be presented at the USCLC Annual Workshop 2026 in Denver, Colorado on March 26, 2026.
  • 24 Sep 2025 According to a SciTech Development media release, the extraordinary interim results from this trial of ST-001 in T-cell Non-Hodgkin Lymphoma (T-cell NHL) across 9 prestigious cancer centers, has led to the successful closure of its Convertible Note Round #3 (CNR 3) at $5.5 million. The round officially closed on 5 Sep 2025 and surpassed its original $3.0 million target by $2.5 million. This investment will aid clinical development in both T-cell NHL and Small Cell Lung Cancer.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top